Tesamorelin Reconstitution Calculator

Classification: Synthetic growth-hormone-releasing hormone analogue and peptide drug substance.

Overview

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It acts within the GHRH signaling pathway and is not the same substance as human growth hormone. The name can refer to the active peptide in FDA-labeled products, whereas a visitor’s container may have different labeling or status; the calculator cannot resolve that distinction.

The FDA label for EGRIFTA SV identifies a specific adult population and indication involving excess abdominal fat associated with HIV lipodystrophy. That narrow authorization should not be generalized to unrelated goals, populations, formulations, or research materials. PepLedger reports the regulatory context without reproducing product preparation or use directions.

The arithmetic tool accepts a mass amount, the liquid volume entered by the visitor, an amount to calculate, and a syringe scale. It then calculates concentration and represented liquid volume. It does not identify an FDA-labeled presentation, interpret a prescription, or turn an approved indication into personal guidance.

Research context

Tesamorelin has been studied in controlled clinical research and has an FDA-labeled indication. The official label is the appropriate source for the authorized product context and population. Research outside that label may involve different questions, endpoints, or formulations and cannot be assumed to carry the same regulatory meaning.

The calculator intentionally avoids product-specific preparation details. It focuses on the mathematical relationship between entered mass, liquid volume, concentration, and syringe scale. If a product label supplies a different unit system or a ready-to-use format, the visitor should rely on the official labeling and should not infer missing values from this tool.

Evidence and regulatory status

The FDA prescribing information linked below states the authorized indication and identifies tesamorelin as a GHRH analogue. It also makes clear that the indication is specific. This page does not extend that indication to other conditions or purposes, and it does not describe an unapproved product as equivalent to the labeled medicine.

Evidence for any use must be read in the context of the studied population, formulation, outcomes, and regulatory document. Approval of a named presentation does not validate material with an uncertain source, composition, or label.

Unit notes

Mass fields use mg or mcg, with 1 mg = 1,000 mcg. Volume is entered in mL. A concentration is the entered mass divided by the entered liquid volume.

U-100 means 100 units per mL, while U-40 means 40 units per mL. These scale definitions do not convert tesamorelin mass by themselves. The visitor’s selected scale and verified concentration are both required.

Limitations

• The calculator cannot verify a prescription label, assess product authenticity, evaluate contraindications or interactions, or determine whether an input belongs to an FDA-labeled presentation. It cannot provide preparation, handling, administration, or product-selection guidance.
• If the label provides insufficient or conflicting values, no arithmetic result can resolve the conflict. Enter only values that are clear and verified for the specific container being considered.

Frequently asked questions

Sources and official references

• EGRIFTA SV (tesamorelin) Prescribing Information — U.S. Food and Drug Administration (2024)
• EGRIFTA SV (tesamorelin) Drug Label — DailyMed, National Library of Medicine (2024)
• Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — Annals of Pharmacotherapy via PubMed (2012)
• Tesamorelin, a human growth hormone releasing factor analogue — PubMed (2009)

Related tools

• Compound calculators
• Peptide reconstitution calculator
• Units-to-mg calculator
• HGH calculator
• CJC-1295 calculator
• PepLedger peptide tracker
• PepLedger on the App Store